CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.12% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Apellis Pharmaceuticals, Inc. - APLS CFD

24.07
0.04%
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.13
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023346 %
Charges from full value of position ($-0.23)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.023346%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001124 %
Charges from full value of position ($0.01)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.001124%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 24.08
Open 24.01
1-Year Change -46.59%
Day's Range 23.97 - 24.47
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 21, 2025 24.07 0.22 0.92% 23.85 24.51 23.85
Mar 20, 2025 24.08 -0.39 -1.59% 24.47 25.07 24.06
Mar 19, 2025 24.74 0.29 1.19% 24.45 25.27 24.10
Mar 18, 2025 24.35 -0.10 -0.41% 24.45 24.94 24.06
Mar 17, 2025 25.05 0.44 1.79% 24.61 25.28 24.37
Mar 14, 2025 24.60 0.39 1.61% 24.21 24.76 24.06
Mar 13, 2025 24.29 -0.26 -1.06% 24.55 25.18 24.20
Mar 12, 2025 25.13 -0.37 -1.45% 25.50 25.87 25.02
Mar 11, 2025 25.47 0.41 1.64% 25.06 25.61 24.69
Mar 10, 2025 25.06 0.11 0.44% 24.95 25.15 24.42
Mar 7, 2025 25.01 0.16 0.64% 24.85 25.43 24.37
Mar 6, 2025 25.26 -0.02 -0.08% 25.28 25.86 24.99
Mar 5, 2025 25.94 0.79 3.14% 25.15 26.06 24.70
Mar 4, 2025 24.97 0.96 4.00% 24.01 25.50 23.72
Mar 3, 2025 24.03 -0.67 -2.71% 24.70 24.99 23.76
Feb 28, 2025 25.05 -0.80 -3.09% 25.85 25.85 24.24
Feb 27, 2025 25.96 -0.25 -0.95% 26.21 27.43 25.94
Feb 26, 2025 26.29 -0.57 -2.12% 26.86 28.02 26.21
Feb 25, 2025 26.84 -0.61 -2.22% 27.45 27.45 26.53
Feb 24, 2025 27.34 -0.06 -0.22% 27.40 27.60 26.87

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
Leverage
2:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam''s base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Industry: Biopharmaceuticals

100 Fifth Avenue
WALTHAM
MASSACHUSETTS 02451
US

People also watch

BTC/USD

84,022.70 Price
-0.210% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 50.00

US100

19,771.90 Price
+0.430% 1D Chg, %
Long position overnight fee -0.0233%
Short position overnight fee 0.0011%
Overnight fee time 21:00 (UTC)
Spread 7.0

XRP/USD

2.38 Price
-0.960% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.01187

ETH/USD

1,985.09 Price
+0.510% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 1.75

Still looking for a broker you can trust?

Join the 700,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading